Veradermics' oral hair loss drug shows strong regrowth in late-stage trial
TL;DR Summary
Veradermics announced that its oral hair-loss medicine VDPHL01 significantly boosted hair growth in a six-month late-stage trial, with men on the drug gaining 30–33 more hairs per cm² versus about 7 in the placebo; 79–86% of participants and 72–84% of investigators reported improvement, signaling promising efficacy for the therapy.
- Veradermics’ hair loss drug succeeds in late-stage trial | STAT statnews.com
- A new version of an old drug is helping men grow back some of their hair MarketWatch
- How This Biotech, Up 25%, Is Taking A Page Out Of Rogaine's Playbook Investor's Business Daily
- A hair-loss pill beat placebo in 519 men, showing growth by Month 2 Stock Titan
- Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss Business Wire
Reading Insights
Total Reads
1
Unique Readers
2
Time Saved
2 min
vs 3 min read
Condensed
89%
462 → 49 words
Want the full story? Read the original article
Read on statnews.com